Takeda Pharmaceutical Co Ltd
TSE:4502

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
TSE:4502
Watchlist
Price: 4 114 JPY -0.19% Market Closed
Market Cap: 6.5T JPY
Have any thoughts about
Takeda Pharmaceutical Co Ltd?
Write Note

Takeda Pharmaceutical Co Ltd
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Takeda Pharmaceutical Co Ltd
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Takeda Pharmaceutical Co Ltd
TSE:4502
Selling, General & Administrative
-ÂĄ1.1T
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Daiichi Sankyo Co Ltd
TSE:4568
Selling, General & Administrative
-ÂĄ696.7B
CAGR 3-Years
-26%
CAGR 5-Years
-20%
CAGR 10-Years
-5%
Otsuka Holdings Co Ltd
TSE:4578
Selling, General & Administrative
-ÂĄ925.7B
CAGR 3-Years
-16%
CAGR 5-Years
-10%
CAGR 10-Years
-4%
S
Shionogi & Co Ltd
TSE:4507
Selling, General & Administrative
-ÂĄ99.9B
CAGR 3-Years
-2%
CAGR 5-Years
10%
CAGR 10-Years
4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Selling, General & Administrative
-ÂĄ108.4B
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
Astellas Pharma Inc
TSE:4503
Selling, General & Administrative
-ÂĄ795.7B
CAGR 3-Years
-14%
CAGR 5-Years
-10%
CAGR 10-Years
-7%
No Stocks Found

Takeda Pharmaceutical Co Ltd
Glance View

Market Cap
6.5T JPY
Industry
Pharmaceuticals

In the ever-evolving landscape of global pharmaceuticals, Takeda Pharmaceutical Co Ltd. stands as a robust and adaptive entity, blending a rich heritage with bold innovation. Originating from Japan, Takeda's journey began over two centuries ago, carving its niche by focusing on value-driven and research-led approaches in the pharmaceutical industry. With its headquarters in Tokyo, the company has fortified its position as one of the global leaders, largely due to its emphasis on research and development that spans across cutting-edge areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. This innovation-centric strategy is not just a nod to the future, but a crucial component that allows Takeda to address pressing health challenges worldwide, continually expanding its pipeline with transformative therapies. Takeda's commercial model revolves around its diverse therapeutic portfolio and strategic collaborations, which are instrumental in capturing growth across various markets. By leveraging its scientific expertise and expanding technological capabilities, the company advances its core business segments while integrating augmented biotechnology solutions through strategic acquisitions and partnerships. The absorption of Shire, a prominent biotechnology firm, stands as a hallmark of Takeda's commitment to enhancing its presence in rare diseases and plasma-derived therapies, thereby widening its global footprint. This focus not only fuels revenue generation from innovative products but also ensures a multidimensional approach to market entry across pivotal regions. Through balancing its inventive drive with operational efficiency, Takeda efficiently monetizes its products, securing its status as a formidable player in the pharmaceutical domain.

Intrinsic Value
5 304.77 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Takeda Pharmaceutical Co Ltd's Selling, General & Administrative?
Selling, General & Administrative
-1.1T JPY

Based on the financial report for Sep 30, 2024, Takeda Pharmaceutical Co Ltd's Selling, General & Administrative amounts to -1.1T JPY.

What is Takeda Pharmaceutical Co Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-7%

Over the last year, the Selling, General & Administrative growth was -7%. The average annual Selling, General & Administrative growth rates for Takeda Pharmaceutical Co Ltd have been -7% over the past three years , -4% over the past five years , and -7% over the past ten years .

Back to Top